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Abstract
myc genes are best known for causing tumors when overexpressed, but recent studies suggest endogenous myc regulates
pluripotency and self-renewal of stem cells. For example, N-myc is associated with a number of tumors including
neuroblastoma, but also plays a central role in the function of normal neural stem and precursor cells (NSC). Both c- and N-
myc also enhance the production of induced pluripotent stem cells (iPSC) and are linked to neural tumor stem cells. The
mechanisms by which myc regulates normal and neoplastic stem-related functions remain largely open questions. Here
from a global, unbiased search for N-Myc bound genes using ChIP-chip assays in neuroblastoma, we found lif as a putative
N-Myc bound gene with a number of strong N-Myc binding peaks in the promoter region enriched for E-boxes. Amongst
putative N-Myc target genes in expression microarray studies in neuroblastoma we also found lif and three additional
important embryonic stem cell (ESC)-related factors that are linked to production of iPSC: klf2, klf4, and lin28b. To examine
the regulation of these genes by N-Myc, we measured their expression using neuroblastoma cells that contain a Tet-
regulatable N-myc transgene (TET21N) as well as NSC with a nestin-cre driven N-myc knockout. N-myc levels closely
correlated with the expression of all of these genes in neuroblastoma and all but lif in NSC. Direct ChIP assays also indicate
that N-Myc directly binds the lif promoter. N-Myc regulates trimethylation of lysine 4 of histone H3 in the promoter of lif and
possibly in the promoters of several other stem-related genes. Together these findings indicate that N-Myc regulates
overlapping stem-related gene expression programs in neuroblastoma and NSC, supporting a novel model by which
amplification of the N-myc gene may drive formation of neuroblastoma. They also suggest mechanisms by which Myc
proteins more generally contribute to maintenance of pluripotency and self-renewal of ESC as well as to iPSC formation.
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Introduction
myc genes encode transcription factors belonging to the basic-
helix-loop-helix-zipper (bHLHZ) superfamily. While Myc proteins
have homology to other bHLHZ proteins and bind to the classical
bHLHZ E-box CACGTG, they appear to be atypical members in
a number of ways. They have the ability to regulate both specific
gene transcription through discrete chromatin events usually at
target gene promoters [1,2] and maintain very large euchromatic
domains [3]. At both specific promoters, but also within much
larger chromatin domains Myc is most strongly linked with
euchromatic marks including acetylation of lysine 9 (AcK9) and
methylation of lysine 4 of histone H3 (triMeK4). Myc is also
unusual in that it binds and influences expression of an extremely
large number of genes, however most often the influence on
expression is surprisingly modest in the range of two-fold [2,4–9].
mycis associated witha widevarietyof cellularfunctionsincluding
proliferation, apoptosis, cellular metabolism and DNA synthesis
(reviewed in [10,11]). Although myc is most well-known for its role in
a large variety of human cancers when deregulated,there is growing
interest in the normal function of myc in stem cells and also myc
activity in induced pluripotent stem cells (iPSC; reviewed in
[12,13]). myc genes are important for the normal functions of a
variety of stem and progenitor cells. For example, in mouse ESC
(mESC), myc plays a central role as an effector of the LIF-STAT
pathway [14] and overexpressed myc confers LIF-independence to
mESC. In the nervous system, disruption of N-myc leads to a
profound impairment of growth and causes microcephaly as well as
retinal defects, phenotypes attributable to perturbance of normal
neural stem and progenitor cell (NSC) biology [15–17]. c- and N-
myc are also essential for normal hematopoietic stem cell (HSC)
function based on gene knockout (KO) studies [18,19]. The mid-
gestational lethality of constitutive c-myc and N-myc KO mice
[20,21] may also be caused in part by stem cell defects. The stem
cell-related functions of myc have in addition been postulated to
contribute to formation of tumors, perhaps through transformation
of normal stem cells into tumor stem cells. This theory is supported
by recent knockdown and knockout studies demonstrating that N-
myc is essential in neural stem cells and precursors of the cerebellum
for medulloblastoma genesis [22], N-myc plays a key role in blocking
the differentiation of cells of origin of medulloblastoma [23], and c-
myc is required for glioma stem cell function [24].
Putative Myc bound genes in mESC have been mapped by
ChIP-chip [25,26], but it remains unclear how Myc and its target
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renewal as well as how this programming could relate to cancer. In
fact, findings conflict on whether Myc operates independently or
in conjunction with other stem cell transcription factors
[25,27,28]. These somewhat conflicting findings suggest a high
degree of complexity in how Myc operates in stem cells.
Here we have found that N-Myc regulates the expression of a
number of genes encoding stem-related factors in neuroblastoma
and in NSC, including lif, klf2, klf4, and lin28b. The regulation of
klf2, klf4, and lin28b occurs both in tumors and stem cells,
suggesting enforced expression of aspects of a pluripotency
program by N-Myc may contribute to neuroblastoma formation.
N-Myc regulation of endogenous LIF production in neuroblasto-
ma implies a potential role of pluripotency-related growth factor
signaling in N-Myc driven neuroblastoma genesis. Together these
data suggest Myc regulation of stem-related factors is an important
mechanism by which it controls stem cell function and contributes
to tumorigenesis.
Results
ChIP-chip indicates that N-Myc binds the lif promoter in a
region containing a canonical Myc E-box, CACGTG
Previously we used ChIP-chip to analyze N-Myc genomic
binding in TET21N neuroblastoma using ENCODE arrays
representing 1% of the human genome [29]. By chance the lif
gene is present on the ENCODE array and we have now
conducted further analysis of data from our previous study
determining that there are several strong N-Myc binding peaks in
the lif promoter in TET21N cells (Fig. 1). In the same region as
these putative binding peaks is a perfect Myc canonical E-box,
CACGTG as well as 6 non-canonical E-boxes.
Expression microarray and RT-PCR suggest that a
number of stem cell related genes are N-Myc targets in
neuroblastoma
Because of the evidence from ChIP-chip of direct binding of N-
Myc to the lif promoter, we conducted further analysis of
expression microarray data on human neuroblastoma with a
Tet-regulated N-myc transgene (TET21N), where we had identi-
fied a widespread euchromatic program regulated by N-Myc [29].
We discovered that lif expression levels and levels of klf2, klf4, and
lin28b from the array studies were sharply decreased in Tet-treated
cells (Fig. S2A). Each of the four stem-related genes was
downregulated 2–3 fold after 3 and 5 days of Tet-driven
repression of N-myc expression. Modest re-elevation of N-myc
due to exhaustion of active Tet in the media at day 7 produced
small increases in expression of some of these genes on the
microarray. To test the expression microarray findings, conven-
tional RT-PCR was conducted on the same RNA samples used in
the previously published study (Fig. S2B). These assays confirmed
the general trends of decreased expression of the 4 stem-related
genes and indicated re-elevation of expression of the stem-related
genes with recovery of N-myc levels at day 7 (Figs. S1 and S2B).
Thus, N-Myc regulates expression of klf2, klf4, lif, and lin28b in
human neuroblastoma.
Figure 1. ChIP-chip indicates strong N-Myc binding of the lif promoter in human neuroblastoma. ChIP-chip data from previous study
[29] was analyzed specifically for lif binding by N-myc. Several strong peaks were observed (brown). The lif promoter is greatly enriched in E-boxes
including one canonical myc E-box CACGTG shown in purple and 6 non-canonical indicated by downward vertical arrows and listed in tabular form
on the bottom left side. The 3 horizontal black bars labeled ‘‘a, b, and c’’ represent the locations of the 3 PCR products from ChIP PCR reactions in
Fig. 4.The genomic locations are listed next to the E-boxes and refer to the last 4 digits of the location, with all being in the 28,970,000 base-pair
range on chromosome 22.
doi:10.1371/journal.pone.0005799.g001
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between N-myc expression and that of klf4, klf2, lif, and
lin28b in neuroblastoma
To measure expression changes in klf2, klf4, lif,a n dlin28b in
neuroblastoma upon N-myc depletion, quantitative RT-PCR (qRT-
PCR) was conducted on the cells treated with the same type of 3, 5,
and 7-day time-course of Tet treatment that was used for the
expression microarray (Fig. 2). There was a clear decrease in
expression in the 4 stem genes at each of the 3 time points of Tet
treatment with generally 4–5 fold reductions in expression. Unlike
in the array experiment where N-myc levels modestly recovered at
day 7 due to exhaustion of Tet, N-myc levels in this subsequent
experiment were reduced nearly 200-fold consistently at days 3, 5,
and 7. The more robust and sustained decrease in N-myc levels in
these cells versus those used for the array may explain the somewhat
more pronounced reductions in expression of klf2, klf4, lif,a n d
lin28b. Together, the expression microarray and both conventional
as well as qRT-PCR results indicate that N-myc regulates expression
of these 4 stem-related genes in TET21N cells.
Reducing N-myc levels rapidly decreases expression of
the four stem cell genes and their levels quickly recover
upon re-elevation of N-myc
We next examined the response of the 4 stem cell related genes to
a shorter time course of N-myc loss and then rapid recovery.
Conventional RT-PCR indicated that by 8 hours of Tet treatment,
klf2 and klf4 were strongly reduced (Fig. 3A). As N-myc levels
recovered from 16 hours onward, klf2 and klf4 gene expression
increased largely in parallel. qRT-PCR was used to quantitatively
measure changes in klf2 and klf4 expression as well as potential
changes in expression of lif and lin28b (Fig 3B). All 4 stem-related
genes were decreased by 8 hours of Tet treatment, likely only
representinga fewhoursoflossofN-myc.Levelsofexpressionofall4
stem related genes then recovered over the rest of the time course,
tightly linked to the observed recovery of N-myc levels.
N-Myc directly binds the lif promoter and regulates
triMeK4
Transcriptional regulation of gene expression can occur in
cascades, particularly when one transcription factor regulates the
expression of another, a common phenomenon amongst stem cell-
related transcription factors including KLF and Sox2 factors. Thus,
itwas importanttouseChIP toaddress whetherN-Mycwasdirectly
binding and regulating expression of lif, as suggested by the ChIP-
chip studies. Potential direct binding of klf2, klf4,a n dlin28b, which
mostlyencodetranscriptionfactors thatcould invokefeedbackloops
as has been previously reported, was also examined (Fig. 4).
To analyze whether N-Myc directly regulated expression of the
stem genes, ChIP was conducted on TET21N cells with or without
3 days of Tet treatment to suppress N-myc expression (Fig. 4).
Controls in these experiments included the use of IgG as a
nonspecific binding control as well as 2 different dilutions of input.
Enriched binding of N-Myc was most pronounced for lif and klf4
promoters. This binding was strongly attenuated in the N-myc
minus cells, also supporting the notion that lif and klf4 are direct
targets of N-Myc in neuroblastoma. Both klf4 and lif promoters
contain canonical myc CACGTG E-boxes in their promoters as
well. The lif E-box is indicated on the ChIP-chip data in Fig. 1 in
purple. Three overlapping but distinct ChIP assays (a, b, and c)
were conducted on the lif promoter region. All showed enhanced
N-Myc binding to the lif promoter, but the results for c were less
pronounced. The main difference between the b and c regions is
that c omits a more 39 noncanonical E-box, CATGTG. The
apparent reduced binding of N-Myc to the c region suggests this
E-box may also contribute to N-Myc binding. ChIP results for N-
Myc binding to the other pluripotency genes suggested some level
of binding but were not conclusive.
Also supporting the notion that lif is a direct N-Myc target in
neuroblastoma is the significant reduction in triMeK4 in N-myc
minus cells at its promoter evident by ChIP (Fig 4). Of the 3 lif
ChIP assays, while a and c showed clear reductions in triMeK4 in
N-Myc minus cells, b exhibited only a slight reduction, possibly
indicative of differential methylation of histones in this region.
Potential modest decreases in triMeK4 were also evident at lin28b
and oct3/4. Interestingly, AcK9 signal was not reduced at any of
the genes tested in the N-myc minus cells and in fact exhibited
consistent increases with loss of N-myc at several genes. Together
these findings indicate that N-Myc directly regulates lif expression
at least in part through maintaining triMeK4 in histone H3
associated with the lif promoter and may do so at other stem-
related genes as well in neuroblastoma.
Figure 2. Expression of klf2, klf4, lif, and lin28b are linked to N-myc levels in human neuroblastoma. qRT-PCR quantifies the changes in
klf2, klf4, lif, and lin28b expression with similar 3–5 fold decreases in expression for each at each time point of Tet treatment (added daily). Error bars
are standard deviation (S.D.) and where not evident it is because the S.D. is so low the bars are so small they do not show up. S.D. throughout this
study were quite low and generally ranged from 0.5–5.5%. TET21N neuroblastoma were treated daily with Tet in this experiment. The data here were
analyzed using the comparative Ct method, but then reanalyzed using the Pffafl method giving essentially identical results (Fig. S1).
doi:10.1371/journal.pone.0005799.g002
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One possibility is that N-Myc regulation of the stem-related
genes is unique to neuroblastoma. Alternatively, N-Myc could
regulate their expression in NSC as well as in neuroblastoma. To
test these possibilities, RT-PCR was conducted on RNA isolated
from control (N-myc flox/flox cre negative) and N-myc null (N-myc
flox/flox nestin-cre) murine NSC [15]. klf2, klf4, and lin28b but
surprisingly not lif, were dependent on N-myc for their expression
in NSC (data not shown). We next used qRT-PCR to measure
expression levels (Fig. 5). klf4 and lin28b were strongly dependent
on N-myc for their continued expression with reductions in the N-
myc null NSC at a similar level to that observed in neuroblastoma,
while klf2 was only weakly regulated. To test the possibility that
other stem cell genes were regulated in NSC by N-Myc, we
conducted RT-PCR for additional stem cells genes and found that
nanog expression was significantly reduced in N-myc null NSC
(Fig. 5). Therefore it appears N-Myc regulation of stem-related
genes occurs both normally in NSC and in neuroblastoma,
however there are some important differences that could play a
role in tumorigenesis. For example, lif may be regulated
specifically in neuroblastoma, while nanog appeared only regulated
in NSC and not in neuroblastoma.
Discussion
The mechanisms by which myc regulates both ESC biology and
the reprogramming required for iPSC formation are important
open questions with critical implications for tumorigenesis as well.
Our study suggests a model (Fig. 6) in which myc contributes to
these pluripotency and self-renewal related functions through
inducing expression of pluripotency-related genes including lif and
those encoding master stem cell factors KLF2, KLF4, and
LIN28B. Our findings indicate that a very similar N-Myc
regulated program is at work in neuroblastoma and could play a
role in its genesis through promoting an aberrant pluripotent state.
Maintaining lif expression and expression of klf2, klf4, and lin28b
are likely two independent mechanisms by which N-Myc
contributes to pluripotency. The regulation of lif expression by
N-Myc is a mechanism by which it may contribute to
neuroblastoma genesis but also ESC and iPSC biology. If N-
Myc stimulates the production of lif during the early stages of
neuroblastoma genesis (Fig. 6), the presence of this potent stem cell
Figure 3. N-myc loss rapidly induces loss of expression of klf2, klf4, lif, and lin28b. (A) RT-PCR for N-myc, klf2, and klf4 was conducted on
Tet21N neuroblastoma cells treated for 8, 16, 24, and 72 hours were conducted along with a loading control (aasdh, a gene we have found does not
vary with modulation of myc levels, for example in the TET21N array experiment). N-myc levels recovered from 8 hours onward due to a suboptimal
dosing of active Tet. (B) qPCR indicates that klf2, klf4, lif, and lin28b levels rapidly decreased as after only 8 hours of Tet treatment and consequent
short-term loss of N-myc. Error bars are S.D.
doi:10.1371/journal.pone.0005799.g003
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autocrine and paracrine signaling that could drive the formation
or maintenance of neuroblastoma stem cells (Fig. 6). However, lif
expression could also be important later in tumorigenesis, perhaps
even in tumor maintenance, as a mechanism for preventing
differentiation of neuroblastoma. Importantly, our studies were
conducted in human neuroblastoma and mouse NSC. While LIF
protein has distinct functions in human and mouse ESC, its role in
NSC generally is less well understood and there is not currently
any evidence of a distinct role for LIF in NSC or neural tumors of
different species. However, there is clear evidence that LIF
regulates self-renewal and pluripotency of both mouse and human
NSC [30,31].
Of interest is our finding that N-Myc does not appear to
regulate lif in NSC, suggesting the regulation of lif in the neuronal
context could be tumor specific. Our discovery of a link between
N-Myc and lif in neuroblastoma also suggests a possible new
treatment for neuroblastoma in the form of LIF antagonists that
would be predicted to induce regression through stimulating
differentiation (Fig. 6). Besides lif expression, we found other
differences in stem-related genes regulated by N-Myc in NSC and
neuroblastoma. For example, while N-Myc did not appear to be
required for nanog expression in neuroblastoma, disruption of N-
myc in NSC caused a pronounced decrease in nanog expression.
These findings suggest that unique stem cell-related targets exist
for N-Myc both in NSC and in neuroblastoma. NSC may be more
Figure 4. Chromatin immunoprecipitation (ChIP) assays indicate that N-Myc directly binds lif and klf4 in neuroblastoma. ChIP was
conducted on Tet21N cells treated daily (3 days) or untreated with Tet. IgG was included as a control along with a 1:50 and 1:200 dilutions of input.
The ChIP’d lif regions a, b, and c are represented by the black bars in Fig. 1. IgG and Input samples were run in parallel as controls.
doi:10.1371/journal.pone.0005799.g004
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genes but have at least partially defective pluripotency.
While we have evidence that N-Myc directly regulates lif and
klf4 through canonical CACGTG E-boxes and triMeK4 in their
promoters, it is also possible that Myc’s induction of lif is an
indirect mechanism by which it acts to also maintain expression of
other important pluripotency associated genes that are dependent
on the action of LIF as a growth factor. Our findings of N-Myc
regulating lif in neuroblastoma also fits with previous work
indicating overexpression of myc confers ectopic LIF-independence
on ESC [14]. Together these data suggest that myc overexpression
in mESC may in part achieve this end through stimulating
expression of endogenous LIF. It is important to note that one
previous study found that N-myc overexpression was correlated
with reduced LIF protein levels [32] in some neuroblastoma
suggesting that N-myc induction of lif may occur only in a subset of
neuroblastoma. Currently it remains unknown what genes mediate
Myc function in mESC to specifically maintain self-renewal and
pluripotency, but the targets we have identified here in
neuroblastoma are candidates as effectors in ESC as well. Also
fitting with our data are the recent observations that c-Myc
regulates lin28 [33] and lin28b [34] expression. In the case of
lin28b, Myc directly binds a canonical CACGTG E-box,
suggesting that our findings of N-Myc regulating lin28b expression
in neuroblastoma and in NSC may be mediated through N-Myc
direct binding of this E-box as well. Since LIN28B functions
through regulation of miRNA processing including that of let-7,
N-Myc activation of LIN28B in neuroblastoma may contribute to
maintenance of an miRNA program that enforces an aberrant
pluripotent state (Fig. 6).
The regulation of lif expression by N-Myc through the
CACGTG E-box also correlates with regulation of triMeK4, a
key euchromatic histone mark associated with active transcription,
within the promoter. Decreased N-Myc expression causes a sharp
decrease in triMeK4 accompanied by a pronounced decrease in
N-Myc binding. There is also some indication that decreased N-
Myc reduces triMeK4 in the promoters of lin28b and oct3/4.
Together these findings suggest N-Myc maintains a transcription-
ally active chromatin state at pluripotency genes in neuroblastoma.
In contrast, at most of the stem cell-related genes tested, decreased
N-Myc surprisingly resulted in increased AcK9 in their promoters.
Given the recruitment of histone acetyltransferases by Myc
proteins, particularly GCN5 [35] and the dependence on N-
Myc for widespread maintenance of AcK9, another key
euchromatic mark, in neuroblastoma [29], it is somewhat
surprising that decreased N-Myc levels would be accompanied
by increased acetylation at these specific genes. At this point it is
unclear what mechanism could be responsible for this change and
why it would occur specifically at stem cell related genes, but it is
possible that pluripotency related genes remain in a poised state
rather than be silenced. An increase in AcK9 modification
accompanying loss of triMeK4 may prevent a fully silenced state.
Figure 5. N-Myc regulates klf2, klf4, and lin28b as well as nanog, but not lif in neurospheres. Control (N-myc flox/flox) and N-myc null
(floxed, nestin-cre) neurospheres were used for qRT-PCR assays. Expression levels in controls were set to 100%. Error bars are S.D.
doi:10.1371/journal.pone.0005799.g005
Figure 6. A model of Myc stem-related function in neuroblas-
toma cells. Two key functions are depicted: growth factor signaling
through LIF and induction of stem-related gene expression through
induced transcription of genes encoding KLF2, KLF4, and LIN28B.
Together these programs are predicted to maintain a ‘‘blast’’-like state
in neuroblastoma tumors through transcriptional and miRNA functions.
doi:10.1371/journal.pone.0005799.g006
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that we found N-Myc regulating 3 other known iPSC-related
genes, lin28b, klf2, and klf4. These data suggest a model in which
overexpressed myc enhances iPSC formation in fibroblasts at least
in part by turning on klf family and lin28b gene expression, and
through inducing expression of lif. Notably our data also provide
the first model for why overexpressed myc, although a potent
enhancer of iPSC formation, may not be formally required for the
process: if expression levels of klf and lin28 as well as other
pluripotency-related genes are high enough, myc may become
more dispensable since it is no longer required to turn on their
expression. Endogenous lif expression may also be dispensable
since ectopic LIF is often added to iPSC media. However,
alternatively, the ability to generate iPSC without added myc may
very well be a result of high levels of endogenous myc expression.
The presence of an iPSC-related gene expression program in
neuroblastoma also raises the concern of the tumorigenicity of
iPSC.
In our previous model, we proposed that myc genes were most
likely contributing to tumorigenesis and perhaps iPSC formation
through both gene specific and global chromatin events. Our new
findings confirm an important role for Myc’s gene specific,
classical transcription factor function in neuroblastoma. The
potential contributions of a more global Myc chromatin function
to neuroblastoma genesis and delineating the mechanisms by
which Myc contributes to iPSC biology await future study.
Particularly important will be functional genomics assays address-
ing Myc chromatin function, not just binding, in iPSC and in
additional types of tumors.
Materials and Methods
Cell Culture
All assays were done on exponentially growing Tet21N human
neuroblastoma cells [36], either untreated or treated with
tetracycline for 3, 5, or 7 at a dose of 1 mg/ml added daily.
Tet21N cells do not contain amplified N-myc and have little if any
endogenous N-myc expression [36]. A different preparation of Tet
was used in the experiment in Fig. 2 that appeared more potent as
it enforced sustained repression of N-myc levels throughout that
time course.
Expression microarray studies
RNA samples were prepared from TET21N cells in biological
duplicate for expression microarray studies and some of the data
from these arrays was previously reported [29]. WG-6 beadchip
arrays from Illumina were used. Data was normalized and
analyzed using Illumina Beadstudio 3.0 and GeneSpringGX
7.3.1 (Agilent Technologies).
qRT-PCR
After isolation with the Ambion RNaqueous kit (AM1912, one
microgram RNA was treated with DNAse, (Invitrogen, 18068-
015), then reverse transcribed with Superscript III First Strand kit
(Invitrogen, 18080-040). Samples were diluted to 5 ng/ml, and
25 ng used in qPCR assays. qPCR assays for mouse neurospheres
were performed in triplicate using LightCycler 480 Probes Master
(Roche, 04 707 494 001) reaction mix with Applied Biosystems
Taqman assays on a Roche LightCycler 480.
Applied Biosystems assays are as follows: klf4 is assay ID
Mm00516104-m1, klf2 is assay ID Mm01244979-g1, lin28b is
assay ID Mm01190674-m1, nanog homeobox assay ID Mm
02019550_s1, and Eukaryotic translation initiation factor 4
gamma 2 (EIF4g2 or Nat1) is assay ID Mm00469036_m1 as a
normalizing gene. NOTE: the actual sequences of reagents for
these assays are proprietary to Applied Biosystems.
Statistical analysis to calculate the standard deviations for
relative expression in different samples was conducted as described
in the Applied Biosystems Taqman protocol handbook. Briefly,
DCT values were obtained and DDCT values (fold differences
between reference and testers) were calculated. The standard
deviation (SD) of the DCT values was calculated as
SD=(SD1
2+SD2
2)
0.5. The DDCT value SD is the same as the
SD of the DCT values since the calibrator value is an arbitrary
constant.
Human QPCR assays for Tet21 and Tet B were performed in
triplicate using LightCycler 480 SYBR Green I reaction mix
(Roche 04 707 516 001) on the same instrument with the following
primer sequences:
klf4 59:ACC AGG CAC TAC CGT AAA CAC A
39: GGT CCG ACC TGG AAA ATG CT
klf2 59:GCG GCA AGA CCT ACA CCA AGA G
39: GTC CCA GTT GCA GTG GTA GGG
lin28b 59: TGA AAG AAG ACC CAA AGG GAA GAC
39: TGA TGA TCA AGG CCA CCA CAG T
lif 59:GCA GTG CCA ATG CCC TCT TTA T
39:CTT GTC CAG GTT GTT GGG GAA C
nanog [37] 59: AAT ACC TCA GCC TCC AGC AGA TG
39: TGC GTC ACA CCA TTG CTA TTC TTC
(The following two primer sets are from the RTPrimer
Database: http://medgen.ugent.be/rtprimerdb/)
N-myc 59:CCG CAA CGA CCT TCG G
39:TCT TTA CCA ACT CCG GCA CG
c-myc 59: CAA ACC TCC TCA CAG CCC ACT
39:TTC GCC TCT TGA CAT TCT CCT C
(The primers below are from Primer Bank: http://pga.mgh.
harvard.edu/primerbank/)
aasdh 59: TCT GAC CTT CGA TCC TTC TGT
39:AGA GAA CGC TGG CTA ATT TTG AT
Relative expression levels for SYBR green RTRPCR data were
calculated using the algorithm from Pfaffl [38].
Standard RT PCR
RNA was isolated with the Ambion RNaqueous kit (AM1912).
One microgram was treated with DNase I (Invitrogen, 18068-015),
reverse transcribed (Invitrogen, 18080-040), and fifty micrograms
run in a standard PCR reaction. Primers for mouse and human
genes not listed below were from Yamanaka’s group [39].
hklf2 mRNA 1–2 59: AGC GTG GCT ACA GAG GGT CTC C
39: CCA AAA ATG CCC ACC TGT CTC T
hlin28bmRNA1–259:TCTCACGAGTTTGGAGCTGAGG
39:AAT GGCACTTCTTTGGCTGAGG
hlif mRNA 1–2 59: CCA GAA GAA GAA GCT GGG CTG T
39: CCT GTG GTC AGG GCT CTT GTA G
mklf2 mRNA L 59: GCG TAC ACA CAC AGG TGA GAA G
39: GTT GGG GAC AGT AAA CTC AAA
GG
mlif mRNA 1–2 59: GGC AAC CTC ATCG AAC CAG ATC A
39: ACC ATC CGA TAC AGC TCC ACC A
mlin28b mRNA 3–4 59: AGG ATG ATT CCA AGA TGC
TAC AA
39: GAG TGC TCT GCC ATT TCT
GAC T
Myc Regulated Stemness Program
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Chromatin samples were prepared precisely as previously
described [40]. For TET21N cells, 4615-cm plates (5610
7 cells)
were crosslinked per experiment. Antibodies used for ChIPs
include the following: N-myc (2 mg Abcam 16898), AcK9 (2.5 mg
06-942 Upstate, and triMeK4 (5 ml Millipore 04-745). 2 mg
Rabbit IgG was used as a background control. Immunoprecipi-
tated chromatin fragments were amplified using the Whole
Genome Amplification kit (Sigma) for 2614 cycles, purified, then
checked for enrichment over control IgG and total samples before
sending for probing of the ENCODE array (Nimblegen Systems).
If inputs between Tet treated (N-Myc -) and untreated (N-Myc +)
were substantially different, samples were re-run.
ChIP Primers
klf4 promoter 5–6 59: GTT CGT TCT CTC TGG TCG GGA
AA
39: GTG CGC CGA GTT TGT TGA TTT
AG
klf2 promoter 3–4: 59: CAA AGC CAC TGG TTC AAG GT
39: GGG TGA AAT GTG AGC TAA
TGT G
lin28b 1–2: 59: GAA TTG TCC AGC AGG GAT TGT
39: CAA TAC TGC ATT CAT GGT TTG A
lif a5 9: AGG TGA TAA AAC TGC CCA TCC
39: TCT GAG TGG TCA GGT CCT TGT
lif b5 9: CAT CTC CTG CAC AAG GAC CTG AC
39: GGT GGA TTA TAG GGC TGA TGT GG
lif c5 9: CAT CTC CTG CAC AAG GAC CTG AC
39: TGG GCA GAA TGG TAG ATG TAG GG
nanog promoter 1–2 59: CCC AGC CCA GTT AAT TTT TGT
39: TGT CCC ATT GTG TCT AGG
GTA A
oct3/4 promoter 1–2 59: CAG TAT CGG GAT GGG AAT G
39: CAC CAC ACC CAA CTT TCA AC
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